Paclitaxel

Name: Paclitaxel
Brand: Selleck Chemicals
SKU: S1150
Rating: 5 (149 reviews)

For research use only.

Catalog No.S1150 Synonyms: NSC 125973, PTX, Taxol, Onxal

149 publications

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Selleck's Paclitaxel has been cited by 149 publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Discov, 2019, 9(2):230-247

PubMed: 30373918 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Adv Mater, 2018, 30(43):e1801621

PubMed: 30203567 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

Cell Stem Cell, 2017, 21(5):650-664

PubMed: 29100014 ( click the link to review the publication )

Clin Cancer Res, 2020, 27 pii: clincanres

PubMed: 32341033 ( click the link to review the publication )

J Cell Biol, 2020, 4;219(5):e201909094

PubMed: 32289147 ( click the link to review the publication )

Theranostics, 2020, 10(6):2727-2743

PubMed: 32194831 ( click the link to review the publication )

Cancer Res, 2020, 10.1158/0008-5472.CAN-19-3466

PubMed: 32054769 ( click the link to review the publication )

Oncogene, 2020, 39(2):454-468

PubMed: 31492900 ( click the link to review the publication )

Cancer Lett, 2020, 472:59-69

PubMed: 31866467 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(4) pii: E964

PubMed: 32295077 ( click the link to review the publication )

Cell Death Dis, 2020, 13;11(5):362

PubMed: 32404870 ( click the link to review the publication )

J Cancer, 2020, 26;11(12):3645-3654

PubMed: 32284761 ( click the link to review the publication )

Cell Discov, 2020, 28;6:26

PubMed: 32351706 ( click the link to review the publication )

Front Oncol, 2020, 1.4125

PubMed: 31998647 ( click the link to review the publication )

Int J Mol Sci, 2020, 30;21(3) pii: E903

PubMed: 32019179 ( click the link to review the publication )

Sci Rep, 2020, 15;10(1):337

PubMed: 31941932 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Biomed Pharmacother, 2020, 16;127:110225

PubMed: 32428834 ( click the link to review the publication )
Cancer Manag Res, 2020, 20;12:2641-2651

PubMed: 32368142 ( click the link to review the publication )

Cell Biol Int, 2020, 44(2):610-620

PubMed: 31743535 ( click the link to review the publication )

J Immunother Cancer, 2020, 8(1)

PubMed: 32152220 ( click the link to review the publication )

Cancer Biol Ther, 2020, 21(5):452-462

PubMed: 32089062 ( click the link to review the publication )

Life Sci, 2020, 246:117428

PubMed: 32057901 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Oncotarget, 2020, 17;11(11):969-981

PubMed: 32215185 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(2):238-250

PubMed: 30664790 ( click the link to review the publication )

Nat Commun, 2019, 10(1):620

PubMed: 30728358 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5367

PubMed: 31772167 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):199

PubMed: 31362778 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0441-3

PubMed: 31645676 ( click the link to review the publication )

Cell Death Differ, 2019, 26(11):2300-2313

PubMed: 30778200 ( click the link to review the publication )

J Control Release, 2019, 294:165-175

PubMed: 30557650 ( click the link to review the publication )

Redox Biol, 2019, 22:101131

PubMed: 30735911 ( click the link to review the publication )

Oncogene, 2019, 38(18):3371-3386

PubMed: 30635656 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(12):2079-2094

PubMed: 30825187 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31766723 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):64

PubMed: 31101119 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):660

PubMed: 31506430 ( click the link to review the publication )

Cells, 2019, 8(7)

PubMed: 31295851 ( click the link to review the publication )

Cancer Biomark, 2019, 10.3233/CBM-190460

PubMed: 31683459 ( click the link to review the publication )

Cells, 2019, 8(6)

PubMed: 31216647 ( click the link to review the publication )
Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-0923

PubMed: 31160383 ( click the link to review the publication )

J Virol, 2019, 93(4)

PubMed: 30487274 ( click the link to review the publication )

Biochem Pharmacol, 2019, 170:113642

PubMed: 31541631 ( click the link to review the publication )

Sci Rep, 2019, 9(1):11153

PubMed: 31371750 ( click the link to review the publication )

J Biol Chem, 2019, 294(46):17471-17486

PubMed: 31594861 ( click the link to review the publication )

J Biol Chem, 2019, 294(20):8161-8170

PubMed: 30940730 ( click the link to review the publication )

J Biol Chem, 2019, 10.1074/jbc.RA119.010732

PubMed: 31628188 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(6):711-719

PubMed: 31585985 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2019, 183:110396

PubMed: 31394424 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 369(3):531-545

PubMed: 30898866 ( click the link to review the publication )

Mol Cell Endocrinol, 2019, 498:110585

PubMed: 31536779 ( click the link to review the publication )

Life Sci, 2019, 224:255-262

PubMed: 30928404 ( click the link to review the publication )

Cell Biosci, 2019, 9:20

PubMed: 30820314 ( click the link to review the publication )

Chem Biol Interact, 2019, 315:108886

PubMed: 31682804 ( click the link to review the publication )

Biomed Rep, 2019, 10(4):218-224

PubMed: 30972217 ( click the link to review the publication )

Biosci Rep, 2019, 39(8)

PubMed: 31316001 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223555

PubMed: 31600301 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:9899-9913

PubMed: 31819487 ( click the link to review the publication )

AAPS PharmSciTech, 2019, 20(5):198

PubMed: 31127389 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 514(4):1154-1159

PubMed: 31103263 ( click the link to review the publication )

Pathol Res Pract, 2019, 215(10):152606

PubMed: 31500928 ( click the link to review the publication )

Orthop Surg, 2019, 11(1):126-134

PubMed: 30592172 ( click the link to review the publication )

Oncotarget, 2019, 10(49):5011-5019

PubMed: 31489111 ( click the link to review the publication )

World J Clin Oncol, 2019, 10(6):222-233

PubMed: 31367531 ( click the link to review the publication )
Oncotarget, 2019, 10(38):3667-3680

PubMed: 31217901 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4116

PubMed: 30297712 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3197-3203

PubMed: 29559562 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(8):e8238

PubMed: 30104419 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2018, 10(26):21825-21835

PubMed: 29897225 ( click the link to review the publication )

J Control Release, 2018, 283:223-234

PubMed: 29864473 ( click the link to review the publication )

Cancer Lett, 2018, 420:60-71

PubMed: 29408653 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):743

PubMed: 29970890 ( click the link to review the publication )

J Clin Med, 2018, 7(12)

PubMed: 30477228 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1134

PubMed: 30429459 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(2):489-504

PubMed: 29794416 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(5):2046-2060

PubMed: 30099455 ( click the link to review the publication )

Neoplasia, 2018, 20(8):826-837

PubMed: 30015158 ( click the link to review the publication )

J Cell Sci, 2018, 131(1)

PubMed: 29192060 ( click the link to review the publication )

Biochem Pharmacol, 2018, 155:102-109

PubMed: 29953843 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(10)

PubMed: 30326563 ( click the link to review the publication )

Front Pharmacol, 2018, 9:403

PubMed: 29765318 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1116

PubMed: 30319428 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):1225

PubMed: 30526520 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 81(2):255-267

PubMed: 29189915 ( click the link to review the publication )
Fitoterapia, 2018, 125:174-183

PubMed: 29355751 ( click the link to review the publication )

Int J Med Sci, 2018, 15(7):738-747

PubMed: 29910679 ( click the link to review the publication )

DNA Repair (Amst), 2018, 63:1-9

PubMed: 29358095 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Clin Cancer Res., 2017, 23(15):4364-4375

PubMed: 28246274 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(18):E3729-E3738

PubMed: 28416665 ( click the link to review the publication )

Clin Chem, 2017, 63(10):1633-1641

PubMed: 28784692 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

Mol Cancer Ther, 2017, 77(22):6282-6298

PubMed: 28424227 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(7):1377-1388

PubMed: 28416606 ( click the link to review the publication )

J Cancer, 2017, 8(9):1655-1664

PubMed: 28775785 ( click the link to review the publication )

Am J Cancer Res, 2017, 7(4):903-912

PubMed: 28469962 ( click the link to review the publication )

Respir Res, 2017, 18(1):52

PubMed: 28340578 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Int J Oncol, 2017, 51(1):257-268

PubMed: 28534954 ( click the link to review the publication )

Front Cell Infect Microbiol, 2017, 7:146

PubMed: 28491824 ( click the link to review the publication )

Biol Reprod, 2017, 97(4):598-611

PubMed: 29025057 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Exp Ther Med, 2017, 14(5):4263-4271

PubMed: 29075340 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51733-51747

PubMed: 28881682 ( click the link to review the publication )

World J Clin Oncol, 2017, 8(1):54-66

PubMed: 28246585 ( click the link to review the publication )

Stem Cell Reports, 2017, 8(6):1617-1629

PubMed: 28552603 ( click the link to review the publication )

Curr Protoc Chem Biol, 2017, 9(2):55-74

PubMed: 28628199 ( click the link to review the publication )
Oncotarget, 2017, 9(1):249-267

PubMed: 29416611 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2082

PubMed: 27182663 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2302-2313

PubMed: 27474148 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2016, 143:463-471

PubMed: 27037784 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(12):1240-1252

PubMed: 27791595 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155052

PubMed: 27148873 ( click the link to review the publication )

Chin Med J (Engl), 2016, 129(20):2469-2475

PubMed: 27748340 ( click the link to review the publication )

Oncotarget, 2016, 7(27):41811-41824

PubMed: 27248820 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2015, 10.1021/am5090226

PubMed: 25811662 ( click the link to review the publication )

J Control Release, 2015, 220(Pt B):727-37

PubMed: 26390807 ( click the link to review the publication )

Environ Sci Technol, 2015, 49(6):3575-83

PubMed: 25695909 ( click the link to review the publication )

Int J Radiat Oncol, 2015, 91(4):807-16

PubMed: 25752395 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.05.005

PubMed: ( click the link to review the publication )

Apoptosis, 2015, 20(10):1373-87

PubMed: 26276035 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0134306

PubMed: 26218638 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23358-71

PubMed: 26160840 ( click the link to review the publication )

Biomacromolecules, 2014, 15(11):4187-94

PubMed: 25251833 ( click the link to review the publication )

Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313 ( click the link to review the publication )

Surgery, 2014, 10.1016/j.surg.2014.10.007

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 453(3):392-7

PubMed: 25268318 ( click the link to review the publication )

J Nanopart Res, 2014, 16:2340

PubMed: ( click the link to review the publication )

J Gen Virol, 2013, 94(Pt 12):2750-8

PubMed: 24062531 ( click the link to review the publication )
Am J Physiol Heart Circ Physiol, 2012, 71(13):4707-19

PubMed: 21555371 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

Bioorg Med Chem, 2012, 21(4):922-31

PubMed: 23306053 ( click the link to review the publication )

RSC Adv, 2011, 1:884-892

PubMed: ( click the link to review the publication )

Gynecol Oncol, 2003, 90(3 Pt 2):S16-21

PubMed: 13129491 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Targets

Microtubule (human endothelial cells) ^[1]

0.1 pM

In vitro

Paclitaxel inhibits non-endothelial type human cells at 10⁴ - to 10⁵ -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. ^[1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. ^[2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
TE-15	NF7rfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnv0TWM2OD1yLkCwNFI5PyEQvF2=	MnHLV2FPT0WU
LC-2-ad	NWH1XJVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;vVIp{UUN3ME2wMlAxODNzNzFOwG0>	MUDTRW5ITVJ?
RL95-2	NHrYdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWWyRnVGUUN3ME2wMlAxODZ4ODFOwG0>	MmOxV2FPT0WU
MZ1-PC	MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXaTWM2OD1yLkCwNFczQSEQvF2=	NH3ESoJUSU6JRWK=
TE-8	NFrr[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHDUY9KSzVyPUCuNFAyOTdizszN	Mn7xV2FPT0WU
SW954	Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFi4OlJKSzVyPUCuNFAyOTlizszN	NFLGeFBUSU6JRWK=
TE-11	M{H4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTBwMECxNlMh\|ryP	M13Pd3NCVkeHUh?=
PSN1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnMfpBKSzVyPUCuNFAyOyEQvF2=	NYL0fYhUW0GQR1XS
MOLT-4	NULK[2RTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LWd2lEPTB;MD6wNFE1QSEQvF2=	NXLBZmpnW0GQR1XS
697	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\VcGJ5UUN3ME2wMlAxOTVizszN	NH3SOpJUSU6JRWK=
ETK-1	NGLSVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nGcWlEPTB;MD6wNFE2OiEQvF2=	NWi3WG11W0GQR1XS
TE-10	M{jtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEftV2VKSzVyPUCuNFAyPTRizszN	NXTJT5pWW0GQR1XS
HUTU-80	M4PMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;p[GdKSzVyPUCuNFAyPjhizszN	M1TQS3NCVkeHUh?=
NTERA-S-cl-D1	NYXMfHBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmj1TWM2OD1yLkCwNlA6KM7:TR?=	M1LtOnNCVkeHUh?=
MFH-ino	M37V[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzUdGZiUUN3ME2wMlAxOjZ6IN88US=>	Mnj0V2FPT0WU
IA-LM	NH\QRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjLdpBKSzVyPUCuNFAzQCEQvF2=	MWTTRW5ITVJ?
MC116	NFq5S2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PLNWlEPTB;MD6wNFI5QSEQvF2=	MlnNV2FPT0WU
RKO	NIjkWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLufFdsUUN3ME2wMlAxOjl6IN88US=>	M2HhZ3NCVkeHUh?=
MRK-nu-1	NI\qRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTBwMECyPVkh\|ryP	NVfqS4ZkW0GQR1XS
VA-ES-BJ	NYnm[3lrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLsTFNKSzVyPUCuNFA{KM7:TR?=	MVLTRW5ITVJ?
KALS-1	M3nZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnnTWM2OD1yLkCwN\|A5KM7:TR?=	NHTl[pFUSU6JRWK=
BB30-HNC	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPWUY1jUUN3ME2wMlAxOzF2IN88US=>	M3vESHNCVkeHUh?=
ACN	NVnKPIg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\0T3VRUUN3ME2wMlAxOzF4IN88US=>	NFfPXGxUSU6JRWK=
TE-9	NILxT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXVO\|FiUUN3ME2wMlAxOzJ4IN88US=>	M1fi[nNCVkeHUh?=
SIG-M5	M1XPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMECzNlch\|ryP	NV\VcopiW0GQR1XS
no-10	MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3e3UGlEPTB;MD6wNFM3OiEQvF2=	M2TrO3NCVkeHUh?=
EW-1	Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH[4bmpKSzVyPUCuNFA{PzFizszN	NUPGXlV[W0GQR1XS
SK-LMS-1	NGi5SlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPNTWM2OD1yLkCwOFAyKM7:TR?=	NUPseZI1W0GQR1XS
GT3TKB	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfwcYRKSzVyPUCuNFA1OzRizszN	MXPTRW5ITVJ?
ES4	NELCbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHY[WFKSzVyPUCuNFA1PDlizszN	M4ewXHNCVkeHUh?=
IMR-5	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nSbmlEPTB;MD6wNFQ2KM7:TR?=	MnfVV2FPT0WU
NCI-H1648	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;QTWM2OD1yLkCwOFY6KM7:TR?=	M3\x[nNCVkeHUh?=
MV-4-11	NFLRZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfEV4ptUUN3ME2wMlAxPDd3IN88US=>	NI\ldFRUSU6JRWK=
SK-UT-1	NUj2TWFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1L4cmlEPTB;MD6wNFQ5KM7:TR?=	MlXvV2FPT0WU
NB13	MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrHZlU{UUN3ME2wMlAxPDlzIN88US=>	MkHkV2FPT0WU
DJM-1	NXrZdHh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILYUXBKSzVyPUCuNFA2OyEQvF2=	MkLGV2FPT0WU
ES8	M1;w[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjKRnBKSzVyPUCuNFA2OzhizszN	NGPVO4FUSU6JRWK=
TE-6	NH3zO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwMEC1O{DPxE1?	NFm1TmNUSU6JRWK=
KS-1	MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwMEC1PFIh\|ryP	NI\aRmdUSU6JRWK=
TE-1	M3rZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fiUmlEPTB;MD6wNFYxPiEQvF2=	M4jHb3NCVkeHUh?=
ATN-1	NF[xcG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwMEC2NFkh\|ryP	Ml3sV2FPT0WU
A4-Fuk	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXCdmJEUUN3ME2wMlAxPjFzIN88US=>	M1PSbnNCVkeHUh?=
ALL-PO	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rZdWlEPTB;MD6wNFY{KM7:TR?=	NGO2c\|dUSU6JRWK=
BE-13	NHzHRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrrWYY6UUN3ME2wMlAxPjN4IN88US=>	NIXPOnFUSU6JRWK=
KM12	MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTBwMEC2N\|ch\|ryP	NYG2UYh1W0GQR1XS
NOS-1	Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\zdGNKSzVyPUCuNFA3PSEQvF2=	NYK2RVR[W0GQR1XS
SW962	NUnmeYZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwMEC2OlIh\|ryP	NYPr[VFMW0GQR1XS
OCUB-M	NHPPdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTXUI5KSzVyPUCuNFA3PjJizszN	NFzjSYxUSU6JRWK=
NCI-H510A	NXnZUIt2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwMEC2OlUh\|ryP	NF\z[IZUSU6JRWK=
EW-16	M1KxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGf1coJKSzVyPUCuNFA3QTRizszN	NXHkZY03W0GQR1XS
KGN	Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PhWGlEPTB;MD6wNFcyOiEQvF2=	NV\5SldNW0GQR1XS
LS-411N	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXmNnUxUUN3ME2wMlAxPzF5IN88US=>	M2LIenNCVkeHUh?=
Becker	M3XIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEC5fWJKSzVyPUCuNFA4OiEQvF2=	Mm\DV2FPT0WU
HC-1	NY\j[Yx{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfrVHNHUUN3ME2wMlAxPzJzIN88US=>	M3n0VHNCVkeHUh?=
CESS	NF3ET\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDDem9lUUN3ME2wMlAxPzN5IN88US=>	Ml\ZV2FPT0WU
KURAMOCHI	NVzSNmJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17aN2lEPTB;MD6wNFc1QCEQvF2=	MWTTRW5ITVJ?
TGBC24TKB	M{XTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYG3c2R[UUN3ME2wMlAxPzV{IN88US=>	NGnjOmtUSU6JRWK=
SW982	M1z4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTBwMEC3OlYh\|ryP	NV;3ZotOW0GQR1XS
HCE-4	MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnDTWM2OD1yLkCwO\|Y4KM7:TR?=	NYL5PI1qW0GQR1XS
LOUCY	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkS0TWM2OD1yLkCwO\|c2KM7:TR?=	M3;6RXNCVkeHUh?=
8-MG-BA	NU\EeoVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXafoxKSzVyPUCuNFA4QTZizszN	M2nwTnNCVkeHUh?=
HT-144	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYr6flI3UUN3ME2wMlAxQCEQvF2=	NH7Tb2hUSU6JRWK=
LXF-289	NXL3ZlBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3l[oNKSzVyPUCuNFA5OThizszN	M{S0XXNCVkeHUh?=
RS4-11	NETORnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTBwMEC4N\|Yh\|ryP	NEjnWIpUSU6JRWK=
DEL	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;0PGlEPTB;MD6wNFg1PSEQvF2=	MXfTRW5ITVJ?
OCI-AML2	M2Xt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwMEC4OVIh\|ryP	MVzTRW5ITVJ?
CCRF-CEM	NX7lOnlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnwcWVKSzVyPUCuNFA5PzFizszN	MmOyV2FPT0WU
A388	MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorNTWM2OD1yLkCwPFc1KM7:TR?=	Mn75V2FPT0WU
KNS-42	M33LNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwMEC4PVEh\|ryP	M{S1[3NCVkeHUh?=
OVCAR-4	NU\nTJZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfqbW5KSzVyPUCuNFA6ODRizszN	NE\xTppUSU6JRWK=
NCI-H1355	NGm5OVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYD6S2JCUUN3ME2wMlAxQTF2IN88US=>	MYDTRW5ITVJ?
BL-70	NVjaXVlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwMEC5N{DPxE1?	M3XWR3NCVkeHUh?=
BL-41	M1HS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLPTWM2OD1yLkCwPVM1KM7:TR?=	NVXreWZOW0GQR1XS
A101D	NYrpOI4zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVyzXZN2UUN3ME2wMlAxQTZizszN	M{fubXNCVkeHUh?=
HL-60	MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPRZpZjUUN3ME2wMlAxQTZ4IN88US=>	NUjrfFBpW0GQR1XS
COR-L279	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NISxUWhKSzVyPUCuNFA6QTlizszN	M2fKTHNCVkeHUh?=
NCI-SNU-16	NVvCdYY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXMXFNuUUN3ME2wMlAyODB6IN88US=>	MYPTRW5ITVJ?
Calu-6	NXXXd2hUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGW5OpVKSzVyPUCuNFExOTJizszN	NXqxb4lWW0GQR1XS
SR	NFT4c\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTBwMEGwNlYh\|ryP	MVzTRW5ITVJ?
QIMR-WIL	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PMT2lEPTB;MD6wNVA{OyEQvF2=	M3XkPHNCVkeHUh?=
LB647-SCLC	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXYclRKSzVyPUCuNFExPTFizszN	NVjaXIdpW0GQR1XS
RPMI-8226	M4P1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLUTWM2OD1yLkCxNVAzKM7:TR?=	MX7TRW5ITVJ?
SK-PN-DW	M3r6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwMEGxNVIh\|ryP	NWjyPXd1W0GQR1XS
SF268	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXYbYtKSzVyPUCuNFEyPTFizszN	M3TOfXNCVkeHUh?=
HD-MY-Z	NX\IS4hnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUK3N4VpUUN3ME2wMlAyOTZ\|IN88US=>	MnXDV2FPT0WU
DOHH-2	M4nGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\rTWM2OD1yLkCxNlA{KM7:TR?=	MYLTRW5ITVJ?
SCC-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnuTVY6UUN3ME2wMlAyOjB2IN88US=>	MYDTRW5ITVJ?
ST486	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwMEGyNFQh\|ryP	NGm1SoJUSU6JRWK=
NALM-6	M12wUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVX3NpJ3UUN3ME2wMlAyOjF2IN88US=>	NX\E[IRVW0GQR1XS
NCI-H1436	NHvSZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkW4TWM2OD1yLkCxNlMyKM7:TR?=	NUT0e2xwW0GQR1XS
KE-37	M1;kPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHOcoQyUUN3ME2wMlAyOjN2IN88US=>	NWfMdVlxW0GQR1XS
RPMI-8402	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMEGyOVYh\|ryP	Mlm3V2FPT0WU
RXF393	NF:1Z4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTBwMEGyOVch\|ryP	M1rKWHNCVkeHUh?=
KARPAS-45	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFu1e5dKSzVyPUCuNFEzPyEQvF2=	NVPjOY5xW0GQR1XS
HOP-62	M4jQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mly0TWM2OD1yLkCxNlc3KM7:TR?=	NHHpT4hUSU6JRWK=
ES1	NF7zcWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fPcmlEPTB;MD6wNVI5QCEQvF2=	NY[xZ\|J3W0GQR1XS
L-363	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\5PJVsUUN3ME2wMlAyOzVzIN88US=>	Mny3V2FPT0WU
GI-1	MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHlTWM2OD1yLkCxN\|c{KM7:TR?=	NGHT[oNUSU6JRWK=
CTV-1	NWf2UXZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2C1V2lEPTB;MD6wNVQ4QCEQvF2=	MXvTRW5ITVJ?
TE-5	NH30NHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTBwMEG0PVYh\|ryP	M4H5[HNCVkeHUh?=
SNU-C2B	M{Swbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPZO3BYUUN3ME2wMlAyPDl4IN88US=>	MUjTRW5ITVJ?
K-562	Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfVNYtKSzVyPUCuNFE2OTZizszN	MWfTRW5ITVJ?
SNB75	NUTDSFV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwMEG1OEDPxE1?	NGPCRmZUSU6JRWK=
MOLT-13	NICwSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwMEG2N\|ch\|ryP	MojkV2FPT0WU
LS-123	NHHEb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwMEG2OlQh\|ryP	NWmyN4trW0GQR1XS
NCI-SNU-5	NFj1WJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljmTWM2OD1yLkCxO\|AyKM7:TR?=	M{fHdHNCVkeHUh?=
Daudi	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3FSXhKSzVyPUCuNFE4ODhizszN	MlzLV2FPT0WU
A253	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7hTWM2OD1yLkCxO\|M5KM7:TR?=	NW[zdWtYW0GQR1XS
TGBC1TKB	NV3LRmdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDzTWM2OD1yLkCxO\|UzKM7:TR?=	NWTofVFwW0GQR1XS
SJSA-1	NWrqXXp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\sdGlEPTB;MD6wNVc3PyEQvF2=	MYTTRW5ITVJ?
NCCIT	NHT5dW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\6TWM2OD1yLkCxO\|Y6KM7:TR?=	MXTTRW5ITVJ?
NCI-H69	NGHMWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnB[HJKSzVyPUCuNFE4PzhizszN	NFrMUnBUSU6JRWK=
SH-4	MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlH1TWM2OD1yLkCxPFk2KM7:TR?=	MoLHV2FPT0WU
HCC1187	M3PtTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwMEG5NlQh\|ryP	M1ixPXNCVkeHUh?=
HCC1599	NIXyblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2focmlEPTB;MD6wNlAzKM7:TR?=	MVPTRW5ITVJ?
ONS-76	M3qyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LYU2lEPTB;MD6wNlA{PiEQvF2=	NYnIb5BRW0GQR1XS
KU812	NVX3U2dHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NICyZmtKSzVyPUCuNFIxOzlizszN	NXLoWVJYW0GQR1XS
ML-2	MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{G5N2lEPTB;MD6wNlA1PyEQvF2=	M{PMenNCVkeHUh?=
HCE-T	NHf5XndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TZSWlEPTB;MD6wNlA6OiEQvF2=	NX34PZZ6W0GQR1XS
NCI-H446	NXvy[3R{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XGWmlEPTB;MD6wNlEyOiEQvF2=	MmPHV2FPT0WU
RPMI-6666	NFHoc3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTUTmdrUUN3ME2wMlAzOTR7IN88US=>	M3HOZXNCVkeHUh?=
MOLT-16	Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWezd2dwUUN3ME2wMlAzOTV\|IN88US=>	NYfKcZY2W0GQR1XS
JiyoyeP-2003	NWPJ[Wg4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHiOFk2UUN3ME2wMlAzOTd4IN88US=>	MULTRW5ITVJ?
MHH-PREB-1	NWPz[ZJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nyemlEPTB;MD6wNlE6OSEQvF2=	NVLCU4pIW0GQR1XS
MC-CAR	Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M173NmlEPTB;MD6wNlMzPiEQvF2=	NEPjVpVUSU6JRWK=
BC-3	NYDpeGdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;jTWM2OD1yLkCyN\|Q1KM7:TR?=	NX\kcnA4W0GQR1XS
KINGS-1	MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwMEKzOVUh\|ryP	MmPjV2FPT0WU
PF-382	M3jPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLNXYg3UUN3ME2wMlAzOzd6IN88US=>	NVLEPVJiW0GQR1XS
J-RT3-T3-5	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLGc5lOUUN3ME2wMlAzOzh\|IN88US=>	MXnTRW5ITVJ?
SF539	M4iwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLKSpRlUUN3ME2wMlAzPDBzIN88US=>	NWrUPHYzW0GQR1XS
LB831-BLC	MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrFVohKSzVyPUCuNFI1QDVizszN	NHTjXJJUSU6JRWK=
DMS-114	NUn3SGRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTY[odWUUN3ME2wMlAzPTB{IN88US=>	NGfUbmFUSU6JRWK=
LB1047-RCC	NIHvWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLRSnUzUUN3ME2wMlAzPTFizszN	NUHTfpRFW0GQR1XS
LB771-HNC	MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMEK1N\|Qh\|ryP	NFrjOHdUSU6JRWK=
BB65-RCC	M3fXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moq3TWM2OD1yLkCyOVM1KM7:TR?=	NIm2UpFUSU6JRWK=
BV-173	MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwMEK1OVQh\|ryP	MXLTRW5ITVJ?
ARH-77	NYTycZRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;ZZphKSzVyPUCuNFI3ODFizszN	NGTzVHZUSU6JRWK=
IST-MEL1	NGHsdYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjhPFdKSzVyPUCuNFI3OjNizszN	M1S5O3NCVkeHUh?=
NB1	NEPZc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPBTWM2OD1yLkCyOlg4KM7:TR?=	M13oeXNCVkeHUh?=
EoL-1-cell	NXmyPWtmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHH5bmVKSzVyPUCuNFI3QDhizszN	NYnoblZHW0GQR1XS
KY821	MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwMEK2PVch\|ryP	Mkn1V2FPT0WU
CMK	NXLyeotWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwMEK3N\|Qh\|ryP	MYPTRW5ITVJ?
NCI-H2126	M1LUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPYTWNPUUN3ME2wMlAzPzZ6IN88US=>	Ml3YV2FPT0WU
NCI-H526	NFHwbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwMEK4PVEh\|ryP	NYTkSlhrW0GQR1XS
COLO-684	NVTETWU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\ITWM2OD1yLkCyPVA5KM7:TR?=	NV7MeWpLW0GQR1XS
NCI-H747	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rTPGlEPTB;MD6wNlk{OyEQvF2=	MYjTRW5ITVJ?
JAR	MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwMEK5OFYh\|ryP	M4LpXnNCVkeHUh?=
MEG-01	M2\Ed2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMEK5O\|gh\|ryP	Ml3PV2FPT0WU
MONO-MAC-6	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jVd2lEPTB;MD6wN\|AzOyEQvF2=	MV;TRW5ITVJ?
IST-SL1	NIP4UJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwMEOwOFIh\|ryP	NHTmd\|lUSU6JRWK=
CPC-N	Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3:xSGlEPTB;MD6wN\|A4QSEQvF2=	MYLTRW5ITVJ?
NCI-H1963	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTITWM2OD1yLkCzNVMyKM7:TR?=	NIDTOnJUSU6JRWK=
K052	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PSO2lEPTB;MD6wN\|I1PyEQvF2=	MWrTRW5ITVJ?
KM-H2	M4HlRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTBwMEOzNFch\|ryP	MVfTRW5ITVJ?
TE-12	M4XMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn35TWM2OD1yLkCzN\|A6KM7:TR?=	NYrDNJF4W0GQR1XS
TK10	M4fDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PDfWlEPTB;MD6wN\|M2PiEQvF2=	NX61NYx6W0GQR1XS
NMC-G1	NHTUXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwMEO0OVIh\|ryP	MULTRW5ITVJ?
no-11	MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwMEO0O\|gh\|ryP	M1WxRXNCVkeHUh?=
NCI-H524	NX7jc4V1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEO2[oRKSzVyPUCuNFM2OjlizszN	M3TWNXNCVkeHUh?=
MHH-CALL-2	NHn0boJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHxTYo{UUN3ME2wMlA{PTZ{IN88US=>	NVXkRXVSW0GQR1XS
GB-1	M1;uT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jLTmlEPTB;MD6wN\|Yh\|ryP	MmjHV2FPT0WU
OPM-2	NF;FbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLZbotkUUN3ME2wMlA{Pjd\|IN88US=>	NUXrZlhZW0GQR1XS
RH-1	NH3tdIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTVTYJmUUN3ME2wMlA{QDF7IN88US=>	NEnNW41USU6JRWK=
NCI-H64	NUT2NpJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\hZWNvUUN3ME2wMlA{QDV5IN88US=>	MYHTRW5ITVJ?
EVSA-T	MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LwUGlEPTB;MD6wN\|kzOyEQvF2=	MXTTRW5ITVJ?
KARPAS-299	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;yV4ZKSzVyPUCuNFM6QCEQvF2=	M3jxeXNCVkeHUh?=
MZ7-mel	NIHzUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwMESwOEDPxE1?	NV\Wbnk5W0GQR1XS
LB373-MEL-D	M{XicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojYTWM2OD1yLkC0NVA2KM7:TR?=	M4HSWHNCVkeHUh?=
HEL	NXHNU4RRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFGxTmlKSzVyPUCuNFQyPCEQvF2=	NXLqcYNtW0GQR1XS
SW872	NGq3V3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLrVXZHUUN3ME2wMlA1OjFizszN	MkK0V2FPT0WU
DU-4475	NUP6bJNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPqTWM2OD1yLkC0NlQ1KM7:TR?=	MXXTRW5ITVJ?
IST-SL2	NY\0PWs{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXWTWM2OD1yLkC0Nlc2KM7:TR?=	MkfpV2FPT0WU
NCI-H82	NV3QWFAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwMESzNFch\|ryP	M4C0RnNCVkeHUh?=
LC4-1	NE\IT\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrNV4dsUUN3ME2wMlA1OzVzIN88US=>	MlvQV2FPT0WU
HDLM-2	NIDUbW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTqbnBRUUN3ME2wMlA1Ozl{IN88US=>	Mm[xV2FPT0WU
MMAC-SF	NGXEcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwMES1N\|Qh\|ryP	NVq1VZp[W0GQR1XS
L-540	NFnSZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7qfGhKSzVyPUCuNFQ3OzlizszN	MVrTRW5ITVJ?
MZ2-MEL	MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDpcpN7UUN3ME2wMlA1PzR{IN88US=>	M2[y[XNCVkeHUh?=
LU-134-A	NFvOR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPGTYdKSzVyPUCuNFQ4PzNizszN	MX;TRW5ITVJ?
UACC-257	Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1OwfmlEPTB;MD6wOFg1QSEQvF2=	NGfiUZBUSU6JRWK=
NCI-H1581	NEXZO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7kXllKSzVyPUCuNFQ6PTNizszN	MWHTRW5ITVJ?
NB17	M1TOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{X6SmlEPTB;MD6wOFk4QSEQvF2=	MXjTRW5ITVJ?
SBC-1	NHTNVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX64dIhVUUN3ME2wMlA2ODR{IN88US=>	NF;0d5BUSU6JRWK=
TALL-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXH3[\|c{UUN3ME2wMlA2ODR3IN88US=>	MmLkV2FPT0WU
NCI-H1304	NVHCWVNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnHZodpUUN3ME2wMlA2OjB6IN88US=>	MmnHV2FPT0WU
NEC8	NUnOW2twT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;s[XNJUUN3ME2wMlA2Ojh4IN88US=>	Mn3KV2FPT0WU
CAL-148	NGK0V2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2j1ZWlEPTB;MD6wOVQ{QSEQvF2=	MXzTRW5ITVJ?
CGTH-W-1	M4HtO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwMEW0OFkh\|ryP	MVnTRW5ITVJ?
NCI-H889	NHTQ[o9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwMEW1PVIh\|ryP	Mof1V2FPT0WU
GR-ST	NXW1O4F5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13Zd2lEPTB;MD6wOVYzOSEQvF2=	M2XESXNCVkeHUh?=
KARPAS-422	NGLvfYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPUUVlKSzVyPUCuNFU3PSEQvF2=	NF3xT5dUSU6JRWK=
RPMI-8866	NVHDeI9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwMEW3NVIh\|ryP	NWm4c4xDW0GQR1XS
SCLC-21H	Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrwbGNwUUN3ME2wMlA2QDh2IN88US=>	NWrUWYRpW0GQR1XS
COR-L88	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwMEW5Nlch\|ryP	Ml\HV2FPT0WU
LU-139	NHjZXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXGNmFKSzVyPUCuNFU6QDZizszN	MXjTRW5ITVJ?
SF126	NEKxcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTBwME[xN\|Mh\|ryP	MV\TRW5ITVJ?
NCI-H1882	NVfVfWwyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHqXnFKSzVyPUCuNFY1OjRizszN	M3[0OHNCVkeHUh?=
EW-24	M33I[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\ocFdKSzVyPUCuNFY1QDNizszN	MXXTRW5ITVJ?
CP67-MEL	M3PoUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnxTWM2OD1yLkC2PFEh\|ryP	M1S5SHNCVkeHUh?=
DG-75	M2TtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nVSWlEPTB;MD6wOlg6QSEQvF2=	M{XldHNCVkeHUh?=
LOXIMVI	NE[2fI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTDWGJKSzVyPUCuNFcxOjhizszN	NGDZU\|lUSU6JRWK=
HH	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljkTWM2OD1yLkC3NVU4KM7:TR?=	MXHTRW5ITVJ?
K5	NVH4U49kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPIT4lKSzVyPUCuNFczOjZizszN	M1XCfnNCVkeHUh?=
EC-GI-10	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DIXWlEPTB;MD6wO\|I2PyEQvF2=	M4fPPHNCVkeHUh?=
SK-N-DZ	NX[1dXRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XmcWlEPTB;MD6wO\|MxPyEQvF2=	NWXYVJZyW0GQR1XS
A3-KAW	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;STWM2OD1yLkC3N\|UyKM7:TR?=	NF7tTVNUSU6JRWK=
MLMA	Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwMEe0OlUh\|ryP	M{LMdnNCVkeHUh?=
LB996-RCC	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDPTWM2OD1yLkC3O\|A4KM7:TR?=	MoXXV2FPT0WU
OS-RC-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jXR2lEPTB;MD6wO\|c1QCEQvF2=	NETifm1USU6JRWK=
CTB-1	NVLje3V4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjjOVJKSzVyPUCuNFc5OSEQvF2=	Mni3V2FPT0WU
IST-MES1	NIDs[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrL[4RCUUN3ME2wMlA4QTF{IN88US=>	NEXTdlVUSU6JRWK=
LS-1034	NXXtNYxKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwMEiwN\|Uh\|ryP	M2LOZnNCVkeHUh?=
HT	M{\Sfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjxTWM2OD1yLkC4NFg3KM7:TR?=	MkjKV2FPT0WU
NCI-H2141	MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwMEixJO69VQ>?	NHvsWHFUSU6JRWK=
LB2518-MEL	NGe0ZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPtTWM2OD1yLkC4NVQyKM7:TR?=	M{fZTXNCVkeHUh?=
GI-ME-N	NXu2WWplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\5W5RKSzVyPUCuNFg1PTJizszN	NFrsfGhUSU6JRWK=
TGW	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3P0bWlEPTB;MD6wPFYxPyEQvF2=	NX;INpQ4W0GQR1XS
SK-NEP-1	NV7MfFhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTKNZpKSzVyPUCuNFg3PDFizszN	NHjxb\|hUSU6JRWK=
NOMO-1	NGPYSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwMEmyO\|Uh\|ryP	NWq3NYFtW0GQR1XS
ES6	M4j4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwMEm1PFkh\|ryP	NV3IbVVZW0GQR1XS
NCI-H209	Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPSTWM2OD1yLkC5O\|g3KM7:TR?=	MoDQV2FPT0WU
GAK	NETuNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3Sx[mlEPTB;MD6xNFE3KM7:TR?=	MlLSV2FPT0WU
BC-1	NV\4fXdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrLSG1RUUN3ME2wMlExOzZzIN88US=>	NYTMUGYzW0GQR1XS
KLE	NVi5PZl4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwMUC0OFMh\|ryP	NH\QRZRUSU6JRWK=
EW-3	M1jz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV62WZY1UUN3ME2wMlExQThizszN	NFL4ZYNUSU6JRWK=
NKM-1	MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfOe\|hNUUN3ME2wMlEyOSEQvF2=	Mk\mV2FPT0WU
D-336MG	Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TyUGlEPTB;MD6xNVI1PCEQvF2=	M1v1SHNCVkeHUh?=
NB69	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwMUGzNFEh\|ryP	NHzE[nlUSU6JRWK=
D-263MG	M1LvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV2ydYo1UUN3ME2wMlEyPzF{IN88US=>	Mo\GV2FPT0WU
KP-N-YS	M{DNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlf3TWM2OD1yLkGyNlkyKM7:TR?=	M2rsc3NCVkeHUh?=
NCI-H1155	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HHdGlEPTB;MD6xNlU2QCEQvF2=	NYTMcWh4W0GQR1XS
BOKU	M1;X[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2flNmlEPTB;MD6xNlU4QSEQvF2=	NYS4W4hVW0GQR1XS
LAMA-84	NUnt[npQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXlRXZsUUN3ME2wMlEzQTlizszN	NH7m[XZUSU6JRWK=
Raji	Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGD2fZFKSzVyPUCuNVMyOTdizszN	M4j5UnNCVkeHUh?=
LU-65	M33GbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DscmlEPTB;MD6xN\|MxPyEQvF2=	M13EXnNCVkeHUh?=
NCI-H187	MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXUTWM2OD1yLkGzPVI1KM7:TR?=	MlTrV2FPT0WU
GCIY	MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LpOWlEPTB;MD6xOFkxOSEQvF2=	M3;oNnNCVkeHUh?=
NCI-H2107	M3nYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vCeGlEPTB;MD6xOVA5KM7:TR?=	M3i0R3NCVkeHUh?=
NCI-H1522	M3\JVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1j4WGlEPTB;MD6xOVI3PiEQvF2=	MVfTRW5ITVJ?
NB6	NUTRd2VMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4j4[GlEPTB;MD6xOVYzOyEQvF2=	NHG5W2FUSU6JRWK=
EM-2	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HIV2lEPTB;MD6xOVcxPiEQvF2=	NETGVllUSU6JRWK=
HCC2218	NYO0cohsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXezOIViUUN3ME2wMlE2QThizszN	NVizXVJ6W0GQR1XS
NCI-H748	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILrO\|NKSzVyPUCuNVY{PzZizszN	MVrTRW5ITVJ?
MS-1	Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEWyN\|hKSzVyPUCuNVY2OzdizszN	MkLIV2FPT0WU
NB5	M1vrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnj6TWM2OD1yLkG2OVk4KM7:TR?=	NXPlcFNZW0GQR1XS
OMC-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjydWc{UUN3ME2wMlE3Pjh6IN88US=>	MmH3V2FPT0WU
NCI-H345	M3GyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDVWGRKSzVyPUCuNVY6OjhizszN	M{ezRXNCVkeHUh?=
L-428	NWDlSII3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3QN40zUUN3ME2wMlE3QTR3IN88US=>	MWDTRW5ITVJ?
SCH	MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmC2TWM2OD1yLkG4Olg2KM7:TR?=	Mom2V2FPT0WU
NCI-H1417	M37RTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\PTWM2OD1yLkG5NlI4KM7:TR?=	NH\WeJhUSU6JRWK=
COLO-320-HSR	Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfOTWM2OD1yLkG5OVMzKM7:TR?=	MXfTRW5ITVJ?
BT-474	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;Jb2lEPTB;MD6yNFg6OiEQvF2=	MYPTRW5ITVJ?
GDM-1	MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTBwMkG5O\|Eh\|ryP	MYTTRW5ITVJ?
NCI-H2196	M4HnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTuS2pKSzVyPUCuNlIzOzVizszN	NUfZXm5nW0GQR1XS
KP-N-RT-BM-1	NFzjbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PPfmlEPTB;MD6yNlM1QSEQvF2=	M{HaSXNCVkeHUh?=
KNS-81-FD	NEDQXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3STWM2OD1yLkKyPVU5KM7:TR?=	NWXiXI9qW0GQR1XS
COLO-668	MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHCTWM2OD1yLkKzOlc2KM7:TR?=	NELweZhUSU6JRWK=
C2BBe1	M{jZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMk[3OFch\|ryP	M2j3fnNCVkeHUh?=
Ramos-2G6-4C10	M{O3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rsdmlEPTB;MD6yOlk2PCEQvF2=	M3\iW3NCVkeHUh?=
CAS-1	M3PseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHlPHVyUUN3ME2wMlI4ODl4IN88US=>	NULneGNpW0GQR1XS
GOTO	MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDyUnJKSzVyPUCuNlc5QTRizszN	MljzV2FPT0WU
LP-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFz6TZBKSzVyPUCuNlgxPTdizszN	NFrHdZVUSU6JRWK=
NCI-SNU-1	NYe2NGxxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwMkm0NlIh\|ryP	M{fPbXNCVkeHUh?=
EB-3	NVPsXVVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXlfVRFUUN3ME2wMlI6QTd7IN88US=>	NWfC[WV{W0GQR1XS
MHH-NB-11	M4DFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TMO2lEPTB;MD6zNFQxOiEQvF2=	MliwV2FPT0WU
SK-N-FI	NYTa[ZNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfvNpduUUN3ME2wMlMyPjl{IN88US=>	M2XoeXNCVkeHUh?=
HCC2157	MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH33PVJKSzVyPUCuN\|M6OTNizszN	MVTTRW5ITVJ?
SIMA	M3zIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\IbHpKSzVyPUCuN\|Q2QDFizszN	Mn7uV2FPT0WU
MDA-MB-134-VI	MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPVeIY{UUN3ME2wMlM3QTJ6IN88US=>	NIrudG1USU6JRWK=
NCI-H1694	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojuTWM2OD1yLkO3JO69VQ>?	MUHTRW5ITVJ?
EHEB	M3TFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rjXGlEPTB;MD6zPVA5PSEQvF2=	M4n5dHNCVkeHUh?=
U-266	NHjoc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzBWmQ3UUN3ME2wMlM6QDR4IN88US=>	MYjTRW5ITVJ?
LC-1F	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\LZWlEPTB;MD60N\|c3PSEQvF2=	MXzTRW5ITVJ?
SHP-77	MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlP4TWM2OD1yLkS3PFU2KM7:TR?=	NHrHW4hUSU6JRWK=
LS-513	M{LRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwNEmzNFch\|ryP	Mn3MV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK / ERK; PubMed: 20068074 Clin Cancer Res Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells. MARCKS (pSer159/163); PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis. Src (pTyr416); PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis. p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; PubMed: 29849942 Oncotarget OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot. Id1; PubMed: 25344919 Oncotarget (A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner. MARCKS; PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.	20068074 26015406 29849942 25344919
Growth inhibition assay	Cell viability; PubMed: 28823711 Biol Psychiatry Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.	28823711
Immunofluorescence	α-tubulin; PubMed: 22904633 Int J Nanomedicine Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel. Rab11a/BV9; PubMed: 29290815 Theranostics Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).	22904633 29290815

In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. ^[4]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
Concentrations: 0.1-100 pM
Incubation Time: 72 hours
Method:
Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

(Only for Reference)

Animal Research:

^[4]

- Collapse

Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
Dosages: 20 mg/kg
Administration: Administered via i.v.
(Only for Reference)

References

[4] Chang J, et al. Breast Cancer Res Treat. 2012.

- Collapse

Solubility (25°C)

In vitro	DMSO	171 mg/mL (200.25 mM)
	Water	Insoluble
	Ethanol	'18 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Paclitaxel SDF

Molecular Weight	853.91
Formula	C₄₇H₅₁NO₁₄
CAS No.	33069-62-4
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NSC 125973, PTX, Taxol, Onxal
Smiles	CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)C4=CC=CC=C4)C5(O)CC(OC(=O)C(O)C(NC(=O)C6=CC=CC=C6)C7=CC=CC=C7)C(=C1C5(C)C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04338399	Not yet recruiting	Drug: Buparlisib & Paclitaxel	Head and Neck Cancer	Adlai Nortye Biopharma Co. Ltd.	July 31 2020	Phase 3
NCT04251169	Not yet recruiting	Drug: Pembrolizumab\|Drug: Paclitaxel	Metastatic Breast Cancer	SOLTI Breast Cancer Research Group\|Merck Sharp & Dohme Corp.	July 15 2020	Phase 2
NCT04252768	Not yet recruiting	Drug: Eftilagimod Alpha\|Drug: Paclitaxel	Metastatic Breast Cancer	Immutep S.A.	June 2020	Phase 1
NCT04374630	Not yet recruiting	Drug: Paclitaxel\|Drug: Afuresertib	Platinum-resistant Ovarian Cancer	Laekna Limited	June 9 2020	Phase 2
NCT04354961	Not yet recruiting	Drug: Almonertinib\|Drug: Paclitaxel and carboplatin	Pulmonary Adenosquamous Carcinoma	Fujian Cancer Hospital\|Jiangsu Hansoh Pharmaceutical Co. Ltd.	June 2020	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?
Answer:
S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.
Question 2:
the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?
Answer:
Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel